Eligibility check
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Step 1 of 5
Where are you located?
We confirm your state so we only show studies you can actually reach.
Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.